Hoping to bag the ResMed dividend? You better be quick!

Is a healthy dividend on the way?

| More on:
A businessman holding a butterfly net looks around hoping to snare a good ASX share investment

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It won't be long before the next Resmed CDI (ASX: RMD) dividend is on its way to shareholders. If investors want to gain access to the payout, they'll need to be quick because it's nearly deadline day!

The ex-dividend date is one of the most important dates when it comes to dividend investing. Investors need to own shares before the ex-dividend date to gain entitlement to the upcoming payment. If investors buy on the ex-dividend date (or afterwards), they'll miss out.

Resmed ex-dividend date

The ex-dividend date for the imminent quarterly payment is on Wednesday, 7 February. That means, to ensure entitlement to this upcoming dividend, investors will need to own Resmed shares by the end of trading tomorrow, 6 February.

The ASX healthcare share is planning to pay this dividend of US 4.8 cents per share on 14 March 2024.

At the current foreign exchange rate, that would translate into a payment of AU 7.3 cents per share. Resmed will provide further details about the size of the dividend in Australian dollar terms on Friday, 9 February.

Profitability performance

Resmed recently announced its FY24 second quarter performance for the three months to 31 December 2023.

It reported that revenue increased by 12% to $1.2 billion, the underlying gross profit margin improved 10 basis points to 56.9%, the underlying (non-GAAP) operating profit improved 20%, and it made an operating cash flow of $272.8 million.

You can read more about that update from our coverage of the quarter.

Management said strong growth in patient flow over the past several quarters had "supported ongoing device growth" and added to replenishment programs for "sustained mask and accessories growth". It was also launching its latest generation platform, AirSense 11, into new markets and geographies.

Resmed share price snapshot

The Resmed share price has fallen more than 8% over the past year.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »